Last update Jan. 10, 2023

Brinzolamide

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a carbonic anhydrase inhibitor (CAI) with actions similar to those of acetazolamide. It is used as 1% drops for topical treatment to lower intraocular pressure or glaucoma, either alone or in conjunction with a topical beta-blocker or prostaglandin analogue.

At the date of the last update we did not find any published data on its excretion in breast milk.

Concentrations of brinzolamide and its metabolite N-desethyl-brinzolamide are low and generally below detection limits (FDA 2015, EMA 2010). For this reason and because it is usually used as a topical treatment its presence in mother’s milk is unlikely. Like most ophthalmologic compounds for topical use, a low dose and poor absorption make it compatible with breastfeeding.

Systemic absorption should be minimized by pressing the tear duct (inner corner of the eye) with the finger for 1 to 2 minutes and administering the dose immediately after breastfeeding. (Belkin 2020, Blumen 2020, Méndez 2012)

Several medical societies and expert authors consider the use of CAI to be safe during breastfeeding. (Blumen 2020)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Brinzolamide in other languages or writings:

Group

Brinzolamide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Brinzolamide in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 384 daltons
Protein Binding 63 %
Tmax 2 hours
4.032 hours

References

  1. Belkin A, Chen T, DeOliveria AR, Johnson SM, Ramulu PY, Buys YM; American Glaucoma Society and the Canadian Glaucoma Society.. A Practical Guide to the Pregnant and Breastfeeding Patient with Glaucoma. Ophthalmol Glaucoma. 2020 Mar - Apr;3(2):79-89. Abstract
  2. Blumen-Ohana E, Sellem E. [Pregnancy & glaucoma: SFO-SFG recommendations]. J Fr Ophtalmol. 2020 Jan;43(1):63-66. Abstract
  3. FDA. Brinzolamide. Drug Summary. 2015 Full text (in our servers)
  4. Méndez-Hernández C. Uso de fármacos antiglaucomatosos durante el embarazo y lactancia. [Use of glaucoma medications during pregnancy and breastfeeding]. Arch Soc Esp Oftalmol. 2012 Dec;87(12):389-91. Abstract
  5. EMA. Brinzolamida. Ficha técnica. 2010 Full text (in our servers)

Total visits

4,779

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM